Short answer
Coherus Oncology, Inc. (CHRS) filed an 8-K current report with the SEC on August 17, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 1.02 (Termination of a Material Definitive Agreement). $55M senior secured term loan funded August 14, 2026, maturing August 2031.
Coherus Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $55M senior secured term loan funded August 14, 2026, maturing August 2031
- Refinanced prior debt maturing May 2029, replacing 8.0% plus three-month SOFR interest
- Floating interest rate: 4.15% plus greater of Prime Rate or 6.75%, implying minimum 10.90%
- Interest-only payments for 36 months, extendable to 48 months upon revenue and market-capitalization milestones
- Substantially all assets, including intellectual property, pledged as collateral; additional $25M and $20M tranches available under conditions
Item 1.02 · Termination of a Material Definitive Agreement
- Prior Loan Agreement fully repaid and terminated on August 14, 2026
- All related security interests released, removing lender claims against pledged assets
- Surviving obligations limited to provisions expressly designated in the agreement
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Coherus Oncology, Inc. 8-K filings
Get the next CHRS 8-K as it lands
Follow CHRS for push alerts, or ask the research agent what this filing means.